Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Company raises the annual revenue guidance from mid-teens to high teens
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra maintains a neutral outlook for healthcare in FY23
Subscribe To Our Newsletter & Stay Updated
